🇺🇸 Levalbuterol HCl Inhalation Solution in United States

11 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Asthenia — 2 reports (18.18%)
  2. Acute Myocardial Infarction — 1 report (9.09%)
  3. Acute Respiratory Failure — 1 report (9.09%)
  4. Bronchitis — 1 report (9.09%)
  5. Cardiac Failure — 1 report (9.09%)
  6. Cardiac Output Decreased — 1 report (9.09%)
  7. Cardiomegaly — 1 report (9.09%)
  8. Chronic Obstructive Airways Disease Exacerbated — 1 report (9.09%)
  9. Dehydration — 1 report (9.09%)
  10. Dyspnoea — 1 report (9.09%)

Source database →

Other Respiratory approved in United States

Frequently asked questions

Is Levalbuterol HCl Inhalation Solution approved in United States?

Levalbuterol HCl Inhalation Solution does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Levalbuterol HCl Inhalation Solution in United States?

Sumitomo Pharma America, Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.